Premium
Exchange transfusion with entirely synthetic red‐cell substitute albumin‐heme into rats: Physiological responses and blood biochemical tests
Author(s) -
Huang Yubin,
Komatsu Teruyuki,
Yamamoto Hisashi,
Horinouchi Hirohisa,
Kobayashi Koichi,
Tsuchida Eishun
Publication year - 2004
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.30127
Subject(s) - heme , in vivo , hemoglobin , human serum albumin , albumin , hemeprotein , recombinant dna , in vitro , serum albumin , biochemistry , chemistry , pharmacology , medicine , biology , enzyme , microbiology and biotechnology , gene
Recombinant human serum albumin (rHSA) incorporating 2‐[8‐{ N ‐(2‐methylimidazolyl)}octanoyloxymethyl]‐5,10,15,20‐[tetrakis{α,α,α,α‐ o ‐(1‐methylcyclohexanoyl)amino}phenyl]porphinatoiron(II) [albumin‐heme (rHSA‐heme)] is an artificial hemoprotein which has the capability to transport O 2 in vitro and in vivo . A 20% exchange transfusion with rHSA‐heme into anesthetized rats has been performed to evaluate its clinical safety by monitoring the circulation parameters and blood parameters for 6 h after the infusion. Time course changes in all parameters essentially showed the same features as those of the control group (without infusion) and rHSA group (with administration of the same amount of rHSA). Blood biochemical tests of the withdrawn plasma at 6 h after the exchange transfusion have also been carried out. No significant difference was found between the rHSA‐heme and rHSA groups, suggesting the initial clinical safety of this entirely synthetic O 2 ‐carrier as a red‐cell substitute. © 2004 Wiley Periodicals, Inc. J Biomed Mater Res 71A: 63–69, 2004